Oncolys BioPharma Inc. announced that it has received a notice from Transposon Therapeutics Inc., licensee of OBP-601 (censavudine, TPN-101), that enrollment has been completed with 42 patients randomized in the Phase IIa, double-blind, placebo- controlled study of OBP-601 in patients with Progressive Supranuclear Palsy (PSP). The target date for publication of the clinical trial results has not yet been determined. In addition, the Phase IIa, double-blind, placebo-controlled study in patients with Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Degeneration (FTD) is recruiting patients.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
700 JPY | 0.00% | -1.41% | +23.46% |
1st Jan change | Capi. | |
---|---|---|
+23.46% | 94.59M | |
-2.35% | 89.33B | |
+3.29% | 41.19B | |
-15.82% | 31.87B | |
+53.49% | 24.52B | |
-14.45% | 15.68B | |
-6.52% | 12.34B | |
-39.65% | 12.23B | |
+6.22% | 8.83B | |
-6.43% | 8.28B |
- Stock Market
- Equities
- 4588 Stock
- News Oncolys BioPharma Inc.
- Oncolys BioPharma Inc. Announces Completion of Enrollment in Phase IIa Clinical Trial of OBP-601 (Censavudine, TPN-101) in Patients with Progressive Supranuclear Pals